VJHemOnc is pleased to be the official media partner for the International Workshop on CAR-T (iwCAR-T) 2021, a high-level discussion forum for research leaders in the field of CAR-T. The world’s leading clinical researchers in the field have shared their perspectives on how to place this evolving understanding in a clinical context and thereby optimize clinical care.

iwCAR-T 2021

The International Workshop on CAR-T (iwCAR-T) 2021
21–23 April 2021 | Virtual Meeting

iwCAR-T 2021

The International Workshop on CAR-T (iwCAR-T) 2021
21–23 April 2021 | Virtual Meeting

VJHemOnc is pleased to be the official media partner for the International Workshop on CAR-T (iwCAR-T) 2021, a high-level discussion forum for research leaders in the field of CAR-T. The world’s leading clinical researchers in the field have shared their perspectives on how to place this evolving understanding in a clinical context and thereby optimize clinical care.

Session 1: CAR-T in AML
Saar  Gill
Clinical update on CAR T-cell therapy for AML
Saar Gill Perelman School of Medicine, Philadelphia, PA, United States
Richard Aplenc
Role of CAR T-cells in the treatment of pediatric AML
Richard Aplenc Children's Hospital of Philadelphia, Philadelphia, PA, United States
Marion Subklewe
CAR-T or BITE in AML?
Marion Subklewe LMU Hospital Munich, Munich, Germany
Rizwan Romee
NK-cells and CAR NK-cells for AML
Rizwan Romee Dana-Farber Cancer Institute, Boston, MA, United States
Session 1: Panel discussion
Session 2: CAR-T in ALL
Reuben Benjamin
Allogeneic CAR-Ts for ALL
Reuben Benjamin King’s College Hospital, London, United Kingdom
Cameron Turtle
Factors associated with durable remissions after CAR-T
Cameron Turtle Fred Hutchinson Cancer Research Center, Seattle, WA, Seattle, WA, United States
Claire Roddie
Adult ALL and CART19
Claire Roddie University College London, London, United Kingdom
Nirali  Shah
Approaches to dual targeting with CAR-Ts
Nirali Shah National Cancer Institute Center for Cancer Research, Bethesda, MD, United States
Bianca  Santomasso
Updates on neurotoxicity
Bianca Santomasso Memorial Sloan Kettering Cancer Centre, New York City, NY, United States
Session 2: Panel discussion
Session 3: CAR-T in CLL
Jordan Gauthier
Combining ibrutinib with CD19 CAR T-cells for CLL
Jordan Gauthier Fred Hutchinson Cancer Research Center, Seattle, WA, United States
Tanya  Siddiqi
Transcend/JCAR – lisocabtagene maraleucel (liso-cel)
Tanya Siddiqi City of Hope, Duarte, CA, United States
David Porter
CAR T-cells for CLL: When can we use the word ‘cure’?
David Porter University of Pennsylvania, Philadelphia, PA, United States
Session 3: Panel discussion
Session 4: CAR-T in Myeloma
Nina  Shah
BCMA CAR-Ts – idecabtagene vicleucel (ide-cel)/bb2121
Nina Shah University of California, San Francisco, CA, United States
Saad Usmani
Ciltacabtagene autoleucel (cilta-cel) – CARTITUDE
Saad Usmani Levine Cancer Institute, Charlotte, NC, Charlotte, NC, United States
Sham Mailankody
Allo-CAR-T
Sham Mailankody Memorial Sloan Kettering Cancer Centre, New York City, NY, United States
Adam Cohen
TCE – BCMA and non-BCMA targets
Adam Cohen Abramson Cancer Center, Philadelphia, PA, United States
Maria-Victoria Mateos
BiTEs vs CARs
Maria-Victoria Mateos University Hospital of Salamanca, Salamanca, Spain
Session 4: Panel discussion
Session 5: Evolution of Cellular Therapies
William Go
Logic-gated cell therapy
William Go A2 Biotherapeutics, Agoura Hills, CA, United States
Renier Bretjens
Innovative CAR designs
Renier Bretjens Memorial Sloan Kettering Cancer Centre, New York City, NY, United States
Session 5: Panel discussion
Session 6: Where Are We with Emerging Cell Therapies in Solid Tumors?
Sebastien Anguille
alloSHRINK – non-gene edited allogeneic CAR-T in mCRC
Sebastien Anguille University of Antwerp, Antwerp, Belgium
Vivek Narayan
CAR T-cells in mCRPC
Vivek Narayan Perelman School of Medicine, Philadelphia, PA, United States
Jennifer Specht
ROR-1 in breast and lung cancer
Jennifer Specht Seattle Cancer Care Alliance, Seattle, WA, United States
Christine Brown
CAR T-cell therapy in glioblastoma
Christine Brown City of Hope, Duarte, CA, United States
Session 6: Panel discussion (part one)
Stanley Riddell
Signaling in solid tumors
Stanley Riddell Fred Hutchinson Cancer Research Center, Seattle, WA, United States
David Hong
Adoptive T-cell therapy ADP-A2M4 targeting MAGE-A4
David Hong MD Anderson Cancer Center, Houston, TX, United States
Amod Sarnaik
Auto TILs lifileucel (LN-144) for metastatic melanoma
Amod Sarnaik H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
Melissa Johnson
Cell therapy trial updates in lung cancer and mesothelioma
Melissa Johnson Sara Cannon Research Institute, Nashville, TN, United States
Session 6: Panel discussion (part two)
Session 7: CAR-T in Lymphoma
Caron Jacobson
Axicabtagene ciloleucel (axi-cel) in DLBCL and FL
Caron Jacobson Dana-Farber Cancer Institute, Boston, MA, United States
Stephen  Schuster
Tisagenlecleucel in DLBCL/FL
Stephen Schuster Perelman School of Medicine, Philadelphia, PA, United States
Jeremy Abramson
Lisocabtagene maraleucel (liso-cel) in DLBCL
Jeremy Abramson Massachusetts General Hospital Cancer Center, Boston, MA, United States
Frederick Locke
Updates in MCL
Frederick Locke H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
David Miklos
Dual CARs
David Miklos Stanford University, Stanford, CA, United States
Mazyar Shadman
Third generation CD20-targeted CAR T-cell therapy
Mazyar Shadman Fred Hutchinson Cancer Research Center, Seattle, WA, United States
Sonali Smith
A new era of targeted therapy
Sonali Smith University of Chicago, Chicago, IL, United States
Session 7: Panel discussion

Visit the CAR-T and Cellular Therapy Focus for the latest updates from leading experts

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter